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ABSTRACT
Coronary arteries supply blood to the myocardium. The blood flow within the coronary arteries
is altered by various compounds produced within the body. Sex hormones such as testosterone
are known to cause the relaxation of large coronary arteries. But the response to testosterone is
greater in in vivo conditions compared to in vitro conditions. We hypothesize that the responses
of LADs (left anterior descending arteries) and its side branches to testosterone are
heterogeneous and testosterone-induced vasodilation is greater in its side branches. Therefore,
our study was designed to determine the effect of testosterone in different-sized coronary
arteries. LADs and one of its side branches were isolated from porcine hearts and mounted in
organ baths to mimic in vivo conditions. The coronary arteries were then preconstricted with
potassium chloride (KCl) and administered increasing concentrations of testosterone to
determine if the responses to testosterone vary within different regions of the coronary
circulation. The testosterone caused significant relaxation in both LADs and its side branches.
However the side branches showed similar responses to testosterone as compared to the larger,
upstream LADs. Further studies on androgen receptor expression using real time PCR indicated
that androgen receptor expression was higher in LADs than its side branches. A third group of
small coronary arteries exhibited greater androgen receptor expression than the LADs and its
side branches. The enhanced testosterone-induced vascular reactivity exhibited in vivo may be
at the level of the small coronary arteries, not the LAD and its side branches.
iv
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INTRODUCTION
Blood flow is the movement of blood through the heart and the blood vessels of the
circulatory system. The myocardium, better known as the heart muscle, needs a constant supply
of oxygen and other nutrients to meet its metabolic demands. The myocardium obtains these via
a localized network of blood vessels known as the coronary arteries and the flow of blood
through this network of arteries is known as the coronary circulation. The two main arteries
supplying blood to the heart are the left and right coronary arteries which originate at the
ascending aorta. The right coronary artery supplies blood to the right atrium and to some
portions of the right ventricle while the left coronary artery supplies blood to the left atrium and
ventricle. The two arteries are interconnected via anastomoses to ensure the continuous supply
of blood throughout the heart.
Regulation of coronary blood flow
The cardiac muscle obtains oxygen and nutrients via the coronary circulation. Blood flow in
the coronary circulation is regulated by various metabolic, endothelial, myogenic, humoral and
nervous mechanisms. Metabolic regulation of coronary circulation is mediated by metabolized
nutrients where oxygen acts as a significant metabolic regulator (Berne, 1963). An increase in
metabolism causes an increase in the utilization of oxygen which in turn produces vasodilatory
substances such as adenosine. In order to counter the increased utilization of oxygen, a balance
is maintained between the oxygen supply and myocardial oxygen consumption (Berne, 1963).
This balance reflects the intracellular myocardial oxygen tension (PO2). With an increase in

oxygen consumption, the PO2 decreases leading to a breakdown of ATP (adenosine triphosphate)
into ADP (adenosine diphosphate) and AMP (adenosine monophosphate). The released
adenosine nucleotides diffuse out of the cell, migrate across the interstitial space and bind to
receptors (A1 and A2A) located in smooth muscle fibers (Hein et al., 1999). Binding of adenosine
to its receptors causes opening of potassium channels and efflux of potassium ions leading to the
hyperpolarization of the membrane in vascular smooth muscle. This hyperpolarization results in
the decrease of calcium influx through calcium channels and leads to the dilation of the coronary
arteries (Komaru et al., 1991). Vasodilation increases the blood flow and delivers more oxygen
to the myocardium thus returning the PO2 to normal.
The binding of adenosine to A1 receptors inhibits adenylyl cyclase thereby reducing cAMP
levels and activates the outward current of potassium. This process of signal transduction from
adenosine receptor to potassium channels is mediated by the pertusis toxin-sensitive G-protein.
This shortens the duration of the action potential and finally reduces the contraction force (Hein
et al., 1999).
Myogenic regulation of blood flow is carried out by the smooth muscle fibers of the blood
vessel. Smooth muscle constriction and relaxation decreases and increases the arterial blood
flow, respectively. Under resting conditions, coronary blood flow remains constant between
mean arterial pressures of 60-140 mmHg. High arterial pressure leads to a sudden stretch of the
blood vessel walls causing the smooth muscle fibers of the vessels to constrict for a few seconds.
This myogenic contraction results in a stretch induced vascular depolarization which results in
the activation of cationic channels enabling an influx of Ca+2, Na+, and K+ ions. The influx of
cations depolarizes the membrane of the smooth muscle and opens the voltage dependent
calcium channels to increase the intracellular calcium levels. The increase in calcium activates
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the actin-myosin interaction leading to smooth muscle contraction (review by Szent, 1975).
Myogenic vasodilation occurs when ATP sensitive K+ channels open to cause an efflux of K+
ions. The efflux of K+ hyperpolarizes the membrane which increases the threshold for cellular
depolarization and finally leads to vasodilation (Haddy et al., 2006).
Endothelial regulation of coronary blood flow is controlled by the endothelium which is a
single layer of cells lining the inner walls of the arteries. The endothelium modulates the activity
of smooth muscle fibers by synthesizing several vasoactive substances that affect relaxation and
contraction of the arterial wall in response to various stimuli. The most important vasodilator is
the endothelium derived relaxing factor, nitric oxide (NO). The endothelial cells experience
sheer stress as the viscous drag of blood flows rapidly along the vascular walls. This stress
contorts the endothelial cells in the direction of blood flow. Stress mainly increases the
intracellular calcium in the endothelium by activation of the phospholipase C pathway. Increased
endothelial cell calcium activates NO synthase which induces synthesis of NO finally leading to
vascular relaxation (Toda et al., 2009).
Humoral regulation involves the control of blood flow by substances secreted into body
fluids. These substances include vasoactive hormones such as angiotensin, calcitonin, vasoactive
-intestinal peptide and atrial natriuretic peptide. Angiotensin induces opening of calcium
channels and thereby increases the calcium influx which leads to vasoconstriction of coronary
arteries.
Steroids
Steroid hormones are naturally occurring organic compounds that are lipophilic in nature.
Steroid hormones primarily include gonadal and adrenocortical hormones which have important
physiological functions such as coordination of behavioral and physiological responses within
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the organism. These hormones act on the central nervous system as well as on peripheral target
tissues. Steroid hormones vary widely in their chemical structure and metabolism.
Metabolism of steroids
Steroids are primarily synthesized by the adrenal glands and the gonads (testis or ovary).
Steroids are secreted into the bloodstream and transported to the target tissue where they initiate
specific responses. Steroid metabolism plays an important role in the production of hormones
and also in regulating the physiological and cellular actions of steroids. Steroids are derived
from cholesterol, the parent compound for all steroids. In the first step of steroid synthesis,
cholesterol is converted to pregnenolone in the presence of C20, C22 lyase. Pregnenolone is the
precursor for progesterone and 17 alpha hydroxyl pregnenolone. Pregnenolone is further
converted to progesterone in the presence of 3 beta hydroxyl steroid dehydrogenase and 4,5
isomerase. Progesterone is converted into corticosterone in the presence of C21 hydroxylase and
C11 hydroxylase. Corticosterone is converted into aldosterone in the presence of C18 hydroxylase
and C18 oxidase. 17 alpha hydroxyl pregnenolone is the precursor for androgens and estrogens.
Initially 17 alpha hydroxyl pregnenolone is converted to dehydroepiandrosterone in the presence
of C17, 20 lyase. Dehydroepiandrosterone is converted to androstenedione in the presence of 3
beta hydroxy steroid dehydrogenase and 4,5 isomerase. In the presence of 17 beta hydroxyl
steroid dehydrogenase, androstenedione is converted to testosterone, which is further converted
to estradiol in the presence of aromatase. Androstenedione is also converted to estrone in the
presence of aromatase. Androgen formation occurs up to androstenedione and
dehydroepiandrosterone in the adrenal glands, whereas androstenedione is further converted to
testosterone only in Leydig cells. Similarly estrogen formation occurs only in ovaries because the
aromatse activity is present only in these tissues.
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Mechanism of action of steroid hormones
Steroid hormones act in genomic and nongenomic pathways. In genomic pathway, steroid
hormones readily diffuse through the cell membrane of the target cell. Once inside, the steroid
hormones bind to intracellular receptors. The hormone-receptor complex then translocates to the
nucleus and interacts with specific DNA sequences known as steroid responsive elements. This
interaction leads to transcription and translation of specific genes. The newly synthesized
proteins may be enzymes involved in specific metabolic activities or the synthesis of other
proteins. In the absence of hormone, the intracellular receptors are bound to chaperones forming
receptor-chaperone complexes which are incapable of binding DNA. When the hormone binds to
the receptor, the chaperone dissociates allowing the receptor to be phosphorylated.
Phosphorylated receptor can bind to the steroid responsive elements in the DNA.

Figure 1: Genomic action of steroids: (figure adapted from Simoncini and Genazzani, 2003).
Steroids are also known to act in nongenomic pathways. Nongenomic actions of steroid
hormones involve the recruitment of signaling pathways that are often associated with cell
5

membrane receptors such as G-protein coupled receptors, ion channels or enzyme-linked
receptors. Through these pathways, steroids rapidly regulate multiple cellular functions.

Figure 2: Nongenomic action of steroids: (figure adapted from Simoncini and Genazzani, 2003).
Coronary heart disease (CHD)
Coronary heart disease (CHD) is the most common type of heart disease caused by
accumulation of cholesterol on the inner walls of arteries. It is one of the leading causes of death
in the United States. Mortality data from Centers for Disease Control and Prevention have
shown that the overall preliminary death rate from CHD was 195.0 per 598,607 people in 2009
(Kochanek et al., 2011).
Extensive clinical studies have identified several controllable and uncontrollable risk factors
for CHD and heart attack. The controllable risk factors include high blood pressure, alcohol
consumption, smoking, diabetes mellitus, obesity, lack of physical activity, and stress.
Uncontrollable risk factors include heredity (children of parents with heart disease have a greater
risk of heart disease than other people), gender (men have a greater risk of heart disease than
woman) and increasing age (people older than 65 have a greater risk of heart attack).
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The role of sex hormones such as estrogen and testosterone in cardiovascular disease has
generated great interest during recent years. Sex hormones directly influence cardiovascular
physiology and it has been proposed that estrogen may protect against the development of
cardiovascular diseases in postmenopausal women (Grady et al., 1992). Estrogens decrease lowdensity lipoprotein, cholesterol and increase high-density lipoprotein (Walsh et al., 1991).
Testosterone is an androgen secreted in the testes of males and to a lesser extent in adrenal
glands and ovaries of females. Testosterone induces the development of secondary sexual
characteristics such as growth spurts, increased body hair, increased muscle mass, deepening of
the voice, maturation of the penis, increased erectile function, spermatogenesis and bone
resorption.
The mechanism of action of testosterone involves both genomic and nongenomic pathways.
In genomic pathways, testosterone regulates gene expression by binding to the androgen receptor
(AR). Testosterone is transported in the bloodstream bound to either sex hormone binding
globulin (SHBG) or albumin. At the target cell, testosterone dissociates from the SHBG, enters
the cell by endocytosis, and is converted to dihydrotestosterone. Dihydrotestosterone binds to the
AR which induces a conformational change in the AR. The hormone receptor complex
translocates into the nucleus where the activated AR complexed to testosterone binds to androgen
response elements (AREs) present within the promoter and enhancer regions of target genes
(Zhou et al., 1994). The ARE-bound AR dimer can either interact directly with components of
the transcription preinitiation complex or recruit other components (transcription factors) that
promote gene transcription. Testosterone also acts through a non-genomic pathway by
potassium channel activation or calcium channel antagonism (Jones et al., 2003).
The putative role of testosterone on vascular reactivity of coronary arteries has received great
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interest during recent years since testosterone directly influences cardiovascular physiology
(Deenadayalu et al., 2001). Men suffering from coronary artery disease (CAD), and myocardial
infarction have lower levels of testosterone than healthy men (English et al., 2000b) and the low
plasma testosterone levels may be associated with increased risk of coronary artery disease in
men (Rosano et al., 2007). The lower testosterone levels are also associated with adverse
cardiovascular risk factors such as premature atherosclerosis, increased visceral adipose tissue,
hyperinsulinemia and increased fibrinogen in humans (Shabsigh et al., 2005). Evidence suggests
that testosterone has beneficial effects on atherogenic blood lipid profile (high amount of low
density lipoprotein, low amount of high density lipoprotein and high triglycerides) and against
atheroma formation (accumulation of fat on inner lining of an artery). Testosterone causes
decreases in the LDL and triglycerides and increases HDL (Rosano and Mercuro, 2001).
Intracoronary infusions of testosterone provide improvement in myocardial ischemia (reduced
blood supply to myocardium) and angina (lack of oxygen supply to myocardium) by inhibiting
plaque formation in blood vessels (Rosano et al., 1999). Administration of testosterone caused
coronary artery dilation and increased coronary blood flow in men suffering from coronary
artery disease (Webb et al., 1999a).
The direct coronary action of testosterone was revealed from studies performed by Webb et al
(1999b), who demonstrated that an intra-coronary infusion of physiological concentrations of
testosterone increased coronary artery diameter and coronary blood flow in men with CAD.
Previous studies on animals demonstrated that testosterone caused vasodilation in rabbit
coronary arteries and aorta (Yue et al., 1995), rat left anterior descending artery (English et al.,
2000a), rat thoracic aorta (Ding and Stallone, 2001), canine coronary artery (Chou et al., 1996),

8

porcine left anterior descending artery (Deenadayalu et al., 2001) and in human coronary arteries
(Webb et al., 1999b).
Testosterone is known to be an acute vasodilator. Testosterone causes the dilation of arteries
by inducing the release of nitric oxide which signals the surrounding smooth muscle to relax
causing vasodilation and finally increasing blood flow. Testosterone also causes vasodilation by
directly acting on vascular smooth muscle through potassium channel activation or calcium
channel antagonism (Yue et al., 1995).
Testosterone shows greater response in vivo compared to in vitro because SHBG is involved
in presentation of testosterone to effector proteins. In in vitro condition absence of SHBG in
target cells may contribute to loss of potency (Webb et al., 1999a). Testosterone acts on large
and small coronary arteries in in vivo conditions, however small coronary arteries may exhibit
greater responses to testosterone due to higher expression of AR in them. The purpose of this
study is to investigate the response of LAD and its side branches to testosterone. We
hypothesize that the regulation of blood flow in the coronary circulation, including vascular
responses to testosterone is heterogeneous and testosterone-induced vasodilation may be greater
in small arteries than large arteries.
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Materials and Methods
Preparation of arterial rings
Fresh porcine hearts (n=13) were obtained from a local abattoir and they were kept on ice
during their transport to the laboratory. The left anterior descending (LAD) artery and its side
branches were dissected from the hearts and cleaned of fat and connective tissue and placed in
Krebs-Henseleit solution.
The arterial rings (length=5mm) were cut from LADs or its side branches and mounted onto
hooks in organ baths (Figure 2) containing 25 ml of Krebs Henseleit solution (pH of 7.4) with
the following composition (in mM): 118.0 NaCl, 4.8 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3,
2.5 CaCl2, and 11.0 glucose. The lower hook was fixed in position and the upper hook was
connected to a force transducer which was coupled to an amplifier and computer-based data
acquisition system for the continuous measurement of arterial tension. A change in arterial
tension due to arterial contraction or relaxation was measured by the transducer and recorded on
a multichannel recorder using Labscribe (2.0) software.
Initially Potassium Chloride (KCl) optimization experiments were performed to determine the
concentration of KCl that can be used for assessing the viability of coronary arteries. This was
done by administering increasing concentrations of KCl (10mM-120mM KCl) to organ baths
containing coronary arteries. The arterial rings were equilibrated for 60 minutes in KrebsHenseleit solution with a passive tension of 7.0 grams for LADs or 1.5 grams for side branches
and all arteries were maintained at 37oC to mimic in vivo conditions. The experimental groups
included LAD vehicle (control), LAD testosterone (treatment), side branch vehicle (control) and
side branch testosterone (treatment). The organ baths were continuously gassed with 95% O2
and 5% CO2. During the period of equilibration, rings were rinsed once every 15 minutes by
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replacing the Krebs-Henseleit solution to remove metabolic wastes produced by the arteries.
Following equilibration, viability of arterial rings was assessed via addition of a known
vasoconstrictor, KCl (60 mM). Only viable arteries (arteries that constricted upon KCl treatment)
were selected for further experimentation. Following the viability test, Krebs-Henseleit solution
(containing 60mM KCl) was replaced with fresh Krebs-Henseleit solution in the organ bath. The
arteries were incubated for 5 minutes in the Krebs-Henseleit solution which allowed the arteries
to return to a normal relaxed state. Then, KCl (15, 30, 45, 60 mM) was added cumulatively to
induce contraction in the vessels followed by induction of relaxation by the cumulative addition
of sodium nitroprusside (SNP10-7-10-3 M). The arterial rings were then exposed to increasing
concentrations of KCl (15, 30, 45, 60mM), followed by testosterone (10-7M-10-3M) or methanol
(the vehicle for dissolving testosterone).
RNA isolation
Fresh porcine hearts were obtained from local abattoir and they were kept on ice during their
transport to the laboratory. Left anterior descending coronary artery (LAD) and its side branches
were dissected from 3 different porcine hearts and cleaned of fat and connective tissue and then
placed in Krebs-Henseleit solution. LAD was categorized as large artery, the branch of LAD
was categorized as medium artery and the branch of medium sized artery was categorized as
small artery. Total ribonucleic acid (RNA) was extracted from large, medium and small
coronary arteries using TRIzol® reagent (Invitrogen, CA, USA). TRIzol® is a monophasic
solution of phenol and guanidine isothiocyanate, which facilitates the isolation of RNA from
tissues by disrupting cells. Initially large, medium and small coronary arteries were homogenized
in 2ml of TRIzol® and then sonicated mildly using sonifier (Brasnon sonifier 150, CT, USA).
The homogenized samples were then incubated at 250 C for 5 minutes to facilitate the
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dissociation of nucleoprotein complexes. Chloroform (Fisher Scientific, NJ, USA) was added to
each of the sonicated arteries and incubated for 5 minutes at room temperature. The samples
were then centrifuged at 12,000g for 15 minutes at 40 C. Following centrifugation, the mixture
separated into a colorless upper aqueous phase containing RNA, an interphase containing DNA
and lower red phenol-chloroform phase containing proteins. The aqueous phase (25 ul)
containing RNA was transferred into new RNAse free eppendorf tubes and RNA was
precipitated from aqueous phase by adding 1ml of isopropanol (Sigma Aldrich, MO, USA). The
samples were incubated at room temperature for 10 minutes and were centrifuged at 15,000g for
15 minutes. The supernatant was removed and the pellet was washed with 80% ethanol (Sigma
Aldrich, MO, USA). The RNA pellet was air dried completely and resuspended in 100 µl of
nuclease free water. 10 µl of DNAse buffer (Applied Biosystems, CA, USA; that is 1/10
volume of RNA solution) was added to the RNA samples, followed by 2 ml of RNAse inhibitor
(Applied Biosystems, CA, USA) and 2 µl of DNAse 1 (Applied Biosystems, CA, USA). RNA
samples were then incubated for 20 minutes at 370 C in a water bath. 1 µl of 2 mercaptoethanol
(Sigma Aldrich, MO, USA) was added to 700 ul of lysis buffer RLT (Quiagen, MY, USA; 4 M
guanidinium thiocyanate, 10 mM Tris-Cl [pH 8.0], 1 mM EDTA). 350ul of 2 mercaptoethanol
and buffer RLT mixture were added to the RNA solution to denature RNase enzymes. Then
250ml of 100% ethanol were added to the RNA samples to promote the selective binding of
RNA to Quiagen column. These samples were loaded onto Quiagen columns and centrifuged at
5,000 rpm for 15 sec at room temperature. The columns were washed twice with 500ul of wash
buffer RPE (Quiagen, MY, USA; 10 mM Tris-Cl [pH 8.0], 1 mM EDTA, 80% ethanol) and
centrifuged at 10,000 rpm for 15 seconds at room temperature. The columns were placed in 2 ml
collection tubes, centrifuged for 1 minute at 15,000 rpm and then placed in 1.5 ml collection

12

tubes. RNA was eluted by adding 50 µl of nuclease free water (Qiagen, MY, USA) to the
RNeasy Minispin columns (Qiagen, MY, USA) followed by centrifugation of columns at 10,000
rpm for 1 minute at room temperature. The RNA elution step was repeated and the resulting
RNA was quantified using nanovue spectrophotometer (GE healthcare, NA, USA). The amount
of RNA isolated from each elution step was shown in Table1.
cDNA generation
cDNA was generated from total RNA using reverse transcriptase enzyme. The reverse
transcription reaction was performed in 20 µl reaction volume containing 3.2 µl of nuclease free
water, 2 µl of RT buffer, 0.8 µl of dNTPs, 2 µl of random primers, 1 µl of reverse transcriptase,
1 µl of RNAse inhibitor and 10 µl of total RNA. The reactions were incubated for 10 minutes at
250 C, 2 hours at 370 C, 5 seconds at 850 C and 40 C overnight. The cDNA samples were then
stored at -200 C until their use.
Real-time PCR
The steady state levels of mRNA in large, medium and small coronary arteries were analyzed
by performing real-time PCR (Stratgene MX 3000 PTm, Agilent Technologies, CA, USA) using
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as control. Real time PCR of AR and
GAPDH genes were performed using Go Taq Q PCR master mix (Promega, WI, USA). Primers
for GAPDH and AR were designed using Primer 3 Software. The primer sequence for GAPDH
was forward primer 5’ ACCAGGTTGTGTCCTCTGACTT 3’ and reverse primer 5’
TGCTGTAGCCAAATTCATTGTC 3’ whereas primer sequences for AR were forward primer
5’ CATATTGAAGGCTATGAGTG 3’ and reverse primer 5’
CCCATCCAGGAATACTGAAT 3’. The 20 µl of cDNA were incubated for 2 minutes at 950 C
followed by 1 minute at 950 C, 30 seconds at 550 C, 30 seconds at 720 C, 1 minute at 950 C, 30
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seconds at 550 C and 30 seconds at 950 C. The products were separated using agarose gel
electrophoresis (1.5% of agarose, run at 125 V) and visualized by ethidium bromide staining and
photographed using Image J software. The flow chart for designing and implementing real-time
PCR assays was shown in Figure3.
Isolation of total RNA

Production of cDNA

Design and validate primers

Perform real time PCR

Analysis of real time PCR data

Figure 3: Flow chart for designing and implementing real time PCR assays.
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Data analysis
Statistical analysis was performed using Sigma Stat (3.1). Since the arterial rings were
subjected to repeated doses of increasing concentrations of KCl, SNP and testosterone in each
treatment group and dose responses recorded as changes in the tension (measured in grams), we
used one-way Repeated Measures ANOVA to analyze the data. Responses of LADs to different
concentrations of KCl were compared by one way Repeated Measures ANOVA. The differences
were considered statistically significant at p<0.05. The changes in gene expression levels of AR
were analyzed using 2-∆∆Ct method (Livak and Schmittgen, 2001).
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Results
KCl optimization
The KCl optimization experiments indicate that increasing concentrations of KCl caused the
contraction of the arteries (fig.5). Artery contraction increased significantly up to a
concentration of 60 mM KCl, with no significant increase beyond that point. Hence 60mM KCl
was used as an optimum concentration for testing the viability of coronary arteries since this
concentration was sufficient to produce a maximal contraction.
Arterial tension studies
The LADs and side branches displayed significant contractions in response to KCl (fig.6).
However, the contraction was greater in LADs compared to the side branches.
Effect of sodium nitroprusside on coronary arteries
The LADs and side branches displayed a significant relaxation in response to sodium
nitroprusside (SNP; fig.7). SNP caused relaxation of both LADs and side branches equally and
there was no significant difference in SNP induced relaxation between the LADs and side
branches.
Effect of Testosterone on coronary arteries
The LADs and side branches exhibited a significant relaxation in response to testosterone
(fig.8). Testosterone caused relaxation of both LADs and side branches at higher concentrations
and there was no significant difference in testosterone-induced relaxation between LADs and
side branches. The relaxation was observed only in the treated arteries whereas there was no
relaxation in control arteries. This indicates that the observed relaxation was caused by
testosterone, and not as a result of the methanol.
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Expression of androgen receptor in coronary arteries
The relative changes in androgen receptor expression from real time PCR experiments were
analyzed by 2-∆∆Ct method. Using this method, data were presented as fold change in gene
expression normalized to endogenous reference gene (GAPDH) and relative to LAD (fig 9).
Thus the depicted fold change in small arteries is high relative to LAD. The fold change in
androgen receptor expression of medium artery was approximately 25% of LAD.
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Figure 4: Schematic diagram of experimental set-up used to perform experiments with coronary
arteries. Created by Donald B.Stratton, Ph.D. (Drakes University, Des Moines, Iowa).
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Figure 5: Histogram depicting the effect of increasing concentrations of KCl on left anterior
descending arteries (n=13) expressed as change in the tension. (d is significantly different from a
and ab, where as bc and cd are significantly different from a) Data are expressed as the
mean±SEM (p<0.05).
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Figure 6: The effect of increasing concentrations of KCl on left anterior descending
artery and side branches (n=13). (a and b are significantly different from c and d). Data
are expressed as the mean±SEM (p<0.05).
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Figure 7: The effect of increasing concentrations of sodium nitroprusside on anterior descending
artery and side branches (n=13). Data are expressed as the mean±SEM (p<0.05).
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Figure 8: The effect of increasing concentrations of testosterone on anterior descending artery
and side branches (n=13). (a, b are significantly different from c, d.). Data are expressed as the
mean±SEM (p<0.05).
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Figure 9: Expression of androgen receptor in coronary arteries (n=3). The changes in
mRNA expression for androgen receptor were measured using Ct method. The Ct method
compares the fold change in gene expression in control to that of LAD medium and small
arteries. Androgen receptor expression was plotted as averages of changes of fold
changes for 3 animals in each treatment group. a and c are not significantly different from
each other, however they are significantly different from b.
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Table 1. The concentrations of RNA isolated from different-sized coronary arteries from
different porcine hearts.

Artery

Concentration of RNA

Coronary arteries isolated from first
porcine heart
Left anterior descending artery (Large artery)

3.6 µg/ml

Medium-sized coronary artery

3.6 µg/ml

Small-sized coronary artery

4.7 µg/ml

Coronary arteries isolated from second
porcine heart
Left anterior descending artery

4.5 µg/ml

Medium-sized coronary artery

3.7 µg/ml

Small-sized coronary artery

3.3 µg/ml

Coronary arteries isolated from third
porcine heart
Left anterior descending artery

2.6 µg/ml

Medium-sized coronary artery

2.4 µg/ml

Small-sized coronary artery

1.6 µg/ml
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Discussion
The present study reports that testosterone induces relaxation in porcine coronary arteries.
The results are consistent with those from previous studies which have demonstrated that
testosterone causes vasodilation in rabbit coronary arteries and aorta (Yue et al, 1995), rat left
anterior descending artery (English et al, 2000), rat thoracic aorta (Ding et al, 2001), canine
coronary artery (Chou et al, 1996), porcine left anterior descending artery (Deenadayalu et al,
2001) and in human coronary arteries (Webb et al, 1999b).
The optimization studies indicated that 60mM KCl caused the greatest vasoconstriction in
porcine coronary arteries. Although not statistically different from other KCl concentrations, the
maximum response was observed at 60mM KCl concentration. Hence we used 60mM KCl as an
optimum concentration for testing the viability of coronary arteries. KCl induced contraction in
both LADs and medium sized coronary arteries. The KCl induced contraction was greater in
LADs compared to medium sized coronary arteries. This may be due to difference in the passive
tensions applied on the LADs and medium sized coronary arteries.
In the resting condition, the concentration of potassium is high while the concentration of
calcium is low within the intracellular environment. Potassium ions move along their
concentration gradient into the extracellular environment through potassium channels and
generate a resting potential of -60 mv (Jones et al, 2004). However, the addition of external KCl
inhibit the movement of potassium ions by disrupting the potassium gradient, which leads to
depolarization of membrane potential and causes activation of voltage dependent calcium
channels and an influx of Ca2+ ions. Increased intracellular calcium level facilitates actin-myosin
interaction leading to smooth muscle contraction.
Similarly sodium nitroprusside (SNP) caused dilation in both LADs and side branches (fig 7).
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These results are consistent with Cogolludo et al, (2001) who reported that SNP induces
vasodilation by activating soluble guanylate cyclase thereby causing a subsequent increase in
cGMP levels. The cGMP further activates SERCA (sarcoplasmic reticulum Ca2+_ATPase) and
Na+/K+ ATPase causing the opening of potassium channels. cGMP may also inhibit the L-type
Ca2+ channels and prevent the Ca2+ influx through these channels and decrease the intracellular
Ca2+ and contractile force in arteries (Cogolludo et al, 2001).
We have investigated the response of LAD and medium sized coronary arteries to
testosterone. Testosterone induced relaxation of both LADs and medium sized branches (fig 8).
When the LADs and side branches were exposed to testosterone there was a gradual increase in
the relaxation with the increasing testosterone concentrations.
Testosterone may regulate cellular functions via interaction with an androgen receptor that is
present on the target cell. However, most of the testosterone may get converted to
dihydrotestosterone at the target cell. The metabolism of testosterone is described in the
following flow chart.
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Metabolism of testosterone:

Cholesterol

Pregnenolone

Progesterone

17 αhydroxy pregnenolone

3β hydroxy 5 androstene 17one (DHEA)

5 androster-3 β, 173 diol (A-Diol)

1 αhydroxy progesterone

4 androstene 3,17dione (A-Dione)

17β-hydroxy 4-androstene 3-one (Testosterone)

17β-hydroxy 5-α -androstene 3-one (Dihydrotestosterone)

Figure 10: Flow chart describing different steps involved in metabolism of testosterone.
The androgen receptor is a protein of approximately 110 kDa with several domains for
androgen binding, nuclear localization, dimerization, DNA binding and transactivation (review
by Zhou et al., 1994). The predominant site of localization of AR in the absence of androgen is
in the cytoplasm, while ligand presence induces the import of AR into the nuclei. Androgen
receptors are also expressed in blood vessels, especially in myocardium (Lin et al., 1990), aorta
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(Tamaya et al., 1993) and vascular smooth muscle (Higashiura et al., 1997). Arterial sex
hormone receptors are probably involved as part of genomic actions of steroids on the level of
the arterial vessel wall. Since LADs showed a significant dilator response to testosterone there
might be high expression of androgen receptor in LADs. The expression of androgen receptor in
LADs and other coronary arteries was investigated by performing Q-PCR. Data indicated high
expression of androgen receptor in LADs compared to medium sized coronary arteries. LADs
responded greatly to testosterone compared to the medium sized coronary arteries, this may be
due to the high expression of androgen receptors in LADs.
Testosterone may act through nongenomic mechanisms. Non-genomic effects can be
indicated as: (i) actions that are too rapid to be compatible with RNA and protein synthesis (i.e.
ensue within seconds to minutes from the challenge with the hormone); (ii) actions that can be
reproduced in the presence of inhibitors of RNA or protein synthesis; (iii) actions that can be
reproduced by using steroid hormones coupled to cell membrane-impermeable molecules; (iv)
actions that steroid hormones induce in cells with highly compacted chromatin, in which RNA
and protein synthesis are absent (such as spermatozoa); and (v) actions that are elicited by steroid
hormones via binding to receptors containing mutations which make them incapable of
activating transcriptional processes (Simoncini and Genazzani, 2003).
Thus if the testosterone induced dilation is through nongenomic pathway the effect might be
fast and not reduced by flutamide (nuclear androgen receptor blocker). Experiments indicated
that testosterone activity is not reduced in presence of flutamide indicating that testosterone acts
via nongenomic pathway (Yue et al., 1995). In nongenomic mechanism testosterone might be
acting on specific binding sites within the smooth muscle cell. Testosterone might be acting by
inhibiting calcium channels and opening potassium channels. Opening of K+ATP channels
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causes the outward flux of potassium, which causes hyperpolarization of membrane, which
increases the threshold for cellular depolarization finally causing vasodilation. However,
testosterone is also known to induce vasodilation by inhibiting voltage gated calcium channels
(VGCC) and store operated calcium channels (SOCC). By acting on these channels testosterone
inhibits the entry of calcium into the cell which is necessary for contraction (Jones et al., 2004).
Testosterone induces vasodilation at very low concentration in vivo (10-50 nm, Webb et al.,
1999). In vitro conditions need higher concentrations (10-100 um, Jones et al., 2003) of
testosterone to induce vasodilation, where as in isolated cell studies concentration of 1 um was
sufficient (Jones et al., 2004). We hypothesized that in vitro conditions need higher
concentrations of testosterone to induce vasodilation in large arteries but not small arteries. The
small coronary arteries may be responding greatly to testosterone due to higher expression of
androgen receptors. However, Q-PCR data indicated that there was no difference in expression
of androgen receptor in LADs and small coronary arteries. Studies by Webb et al 1999,
demonstrated that the response is high in isolated cells of coronary arteries in in vivo condition
because SHBG is involved in presentation of testosterone to effector proteins. In in vitro
condition absence of SHBG in target cells contributes to loss of potency (Webb et al., 1999a).
SHBG is a carrier protein which plays an important role in regulating the amount of unbound
steroid in the blood. It is a homodimer of subunits that is bound noncovalently and contains one
steroid binding site (Petra, 1991). SHBG binds to 17 beta hydroxyl steroids (testosterone and
dihydroxytestosterone) in a 1:1 ratio. The majority of the testosterone and dihydroxytestosterone
(60%) are bound to SHBG and only 4% remain in unbound state in the serum (Heinlein and
Chang, 2002).
SHBG has high affinity for dihydrotestosterone and testosterone and low affinity for
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estradiol; however, SHBG binds to dihydrotestosterone twice as strongly as testosterone
(Pearlman and Crepy, 1996). SHBG is mainly involved in transportation of testosterone to the
target tissue. It is responsible for correct orientation of testosterone within the target membrane.
This orientation of testosterone to the smooth muscle cell is critical in determining the potency
(Heinlein and Chang, 2002). At the target tissue, the SHBG maintain the steady state
concentrations of free hormone, which is necessary for diffusion of steroids across the cell
membranes (Mendel, 1992). This passive diffusion of SHBG across the cell membrane is
enhanced by SHBG receptors (Rosner, 1990). SHBG receptors promote uptake by either
sequestration (Avvakumov, 1991) or endocytosis of SHBG-steroid complex (Porto et al, 1995).
SHBG plays an important role in correct orientation of testosterone within the target
membrane thus increasing the potency of testosterone. The response of coronary arteries to
testosterone is greater in in vivo condition because of the following reasons: 1) SHBG which
increases the potency of testosterone is absent in in vitro conditions, 2) AR might be inactive
and 3) Testosterone is converted to dihydrotestosterone in in vivo conditions where as the
experiments performed in in vitro conditions used testosterone rather than dihydrotestosterone.
However, studies in presence of AR blocker and SHBG might be helpful in understanding the
mechanism of action of testosterone in detail.
In summary, the goal of this study was to determine the response of different sized coronary
arteries to testosterone. Testosterone induces vasodilation in both LADs and side branches.
LADs and side branches exhibited similar responses to testosterone. Testosterone might be
causing the vasodilation via a nongenomic pathway by acting through the AR. This study was a
crucial attempt to describe the relaxation effect of testosterone in smaller coronary arteries. The
results obtained form an important foundation for future research in determining whether
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testosterone acts differentially throughout the coronary circulation. Further studies involving
large, medium and small coronary arteries in the presence of AR blocker and SHBG may be
helpful in determining the mechanism of action of testosterone in coronary arteries.

31

REFERENCES:
1) Avvakumov GV. Membrane recognition of steroid–glycoprotein complexes: a model for
steroid delivery to the target cells. Lectins and Cancer 263–272, 1991.
2) Berne RM. Cardiac nucleotides in hypoxia: possible role in regulation of coronary blood
flow. American Journal of Physiology 204:317–322, 1963.
3) Chou TM, Sudhir K, Hutchison SJ, Ko E, Amidon TM and Collins P and Chatterjee K.
Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo.
Circulation 94:2614–2619, 1996.
4) Cogolludo AL, Vizcaino FP, Arnaez FZ, Ibarra M, Lopez GL, Miranda VL and Tamargo J.
Mechanisms involving SNP-induced relaxation and [Ca2+]i reduction in piglet pulmonary and
systemic arteries. British Journal of Pharmacology 132:959 -967, 2001.
5) Deenadayalu VP, White RE, Stallone JN, Gao X and Garcia AJ. Testosterone relaxes
coronary arteries by opening the large-conductance, calcium-activated potassium channel.
American Journal of Physiology-Heart and Circulatory Physiology 281:1720-1727, 2001.
6) Ding AQ and Stallone JN. Testosterone-induced relaxation of rat aorta is androgen structure
specific and involves K+ channel activation. Journal of Applied Physiology 91:2742–2750,
2001.
7) English KM, Jones RD, Jones TH, Morice AH and Channer KS. Aging reduces the
responsiveness of coronary arteries from male wistar rats to the vasodilatory action of
testosterone. Clinical Science 99:77–82, 2000a.
8) English KM, Mandour O, Steeds RP, Diver MJ, Jones TH and Channer KS. Men with
coronary artery disease have lower levels of androgens than men with normal coronary
angiograms. European Heart Journal 11:890-894, 2000b.

32

9) Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL and Cummings
SR. Hormone replacement therapy to prevent disease and prolong life in postmenopausal
women. Annals of Internal Medicine 117:1016-1037, 1992.
10) Haddy FJ, Vanhoutte PM and Feletou M. Role of potassium in regulating blood flow and
blood pressure. American Journal of Physiology Regulatory Integrative and Comparative
Physiology 290:546–552, 2006.
11) Hein TW, Belardinelli L, and Kuo L. Adenosine A2A receptors mediate coronary
microvascular dilation to adenosine: role of nitric oxide and ATP-sensitive potassium
channels. Journal of Pharmacology and Experimental Therapeutics 291:655-664, 1999.
12) Heinlein CA and Chang C. The roles of androgen receptors and androgen-binding proteins in
non-genomic androgen actions. Molecular Endocrinology 16:2181-2187, 2002.
13) Higashiura K, Mathur RS and Halushka PV. Gender-related differences in androgen
regulation of thromboxane A2 receptors in rat aortic smooth muscle cells. Journal of
Cardiovascular Pharmacology 29:311–315, 1997.
14) Jones RD, Pugh PJ, Jones TH and Channer KS. The vasodilatory action of testosterone: a
potassium-channel opening or a calcium antagonistic action. British Journal of
Pharmacology 138:733 -744, 2003.
15) Jones RD, English KM, Jones TH and Channer KS. Testosterone-induced coronary
vasodilation occurs via a nongenomic mechanism: evidence of a direct calcium antagonism
action. Clinical Science 107:149-158, 2004.
16) Kochanek KD, Xu J, Murphy SL, Minino AM and Kung HC. Deaths: Preliminary data for
2009. National Vital Statistical Reports. 59:4, 2011.

33

17) Komaru T, Lamping KG, Eastham CL and Dellsperger KC. Role of ATP-sensitive potassium
channels in coronary microvascular autoregulatory responses. Circulation Research 69:1146115, 1991.
18) Lin AL, Schultz JJ, Brenner RM and Shain SA. Sexual dimorphism characterizes baboon
myocardial androgen receptors but not myocardial estrogen and progesterone receptors.
Journal of Steroid Biochemistry and Molecular Biology 37:85–95, 1990.
19) Livak JK and Schmittgen TD. Analysis of relative gene expression data using real-time
quantitative PCR and method. Methods 25:402-408, 2001.
20) Mendel CM. The free hormone hypothesis distinction from the free hormone transport
hypothesis. Journal of Andrology 13:107–116, 1992.
21) Pearlman WH and Crepy O. Steroid-protein interaction with particular reference to
testosterone binding by human serum. Excerpta Medica Internal Congress Series 111:48,
1996.
22) Petra PH. The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent
developments on the structure, molecular biology and function. Journal of Steroid
Biochemistry and Molecular Biology 40:735-753, 1991.
23) Porto CS, Lazari MF, Abreu LC, Bardin CW and Gunsalus GL. Receptors for androgenbinding proteins: internalization and intracellular signalling. Journal of Steroid Biochemistry
Molecular Biology 53:561–565, 1995.
24) Shabsigh R, Katz M, Yan G and Makhsida N. Cardiovascular issues in hypogonadism and
testosterone therapy. American Journal of Cardiology 96:67-72, 2005.

34

25) Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, Monica PL,
Bonfigli B, Volpe M and Chierchia SL. Acute anti-ischemic effect of testosterone in men
with coronary artery disease. Circulation 99:1666–1670, 1999.
26) Rosano GM and Mercuro, G. Antianginal and lipid-lowering effects of chronic oral androgen
supplementation in elderly male patients with coronary heart disease. Journal of American
College of Cardiology 37:254A, 2001.
27) Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, Mercuro G, Volterrani
M, Aversa A and Fini M. Low testosterone levels are associated with coronary artery disease
in male patients with angina. International Journal of Impotence Research 19:176-82, 2007.
28) Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding
globulin: recent advances. Endocrine Reviews 11:80–91, 1990.
29) Simoncini T and Genazzani AR. Nongenomic actions of sex steroid hormones. European
Journal of Endocrinology 148:281–292, 2003.
30) Szent AG. Calcium regulation of muscle contraction. Biophysical Journal 15:707–723, 1975.
31) Tamaya T, Misao R, Nakagawa M, Itoh T, Wada K, Fujimoto J and Imai A. Estrogen and
androgen receptors in aorta of the rabbit and regulation by estrogen and androgen. Research
Communications in Chemical Pathology and Pharmacology 82:3–11, 1993.
32) Toda N, Ayajiki K and Okamura T. Cerebral blood flow regulation by nitric oxide: recent
advances. Pharmacological Reviews 61:62-97, 2009.
33) Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V and Sacks FM. Effects of
postmenopausal estrogen replacement on the concentrations and metobolism of plasma
lipoproteins. New England Journal of Medicine 325:1196-1204, 1991.

35

34) Webb CM, Adamson DL, Zeigler D and Collins P. Effect of acute testosterone on
myocardial ischemia in men with coronary artery disease. American Journal of Cardiology
83:437–439, 1999a.
35) Webb CM, McNeill JG, Hayward CS, Zeigler D and Collins P. Effects of testosterone on
coronary vasomotor regulation in men with coronary heart disease. Circulation 100:1690–
1696, 1999b.
36) Yue P, Chatterjee K, Beale C, Wilson PA and Collins P. Testosterone relaxes rabbit coronary
arteries and aorta. Circulation 91:1154–1160, 1995.
37) Zhou ZX, Wong CI, Sar M and Wilson EM. The androgen receptor: an overview. Recent
Progress in Hormone Research 49:249–274, 1994.

36

